GRWD-5769 is under clinical development by Grey Wolf Therapeutics and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase II drugs for Adenocarcinoma Of The Gastroesophageal Junction have a 51% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GRWD-5769’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GRWD-5769 overview
GRWD-5769 is under development for the treatment of solid tumors including head and neck squamous cell carcinoma, cervical cancer, gastric cancer, urothelial cancer, gastric/gastro-esophageal adenocarcinoma, esophageal squamous cell carcinoma and hepatocellular carcinoma. It acts by targeting endoplasmic reticulum aminopeptidase 1 (ERAP1). It is administered through oral route.
Grey Wolf Therapeutics overview
Grey Wolf Therapeutics (Grey Wolf) is a biotechnology company specializing in pharmaceutical drug discovery and development. The company’s lead products include GRWD5769, which is a potent and selective oral ERAP1 inhibitor that has shown the potential to elicit a powerful and differentiated immune response against tumors. Grey Wolf’s other product GRWD0715 is advancing through preclinical development as a potential treatment for autoimmune disease. Grey Wolf collaborates also investigating an ERAP2 drug discovery program. The company works in collaboration with a network of academic institutions and CROs, including the University of Oxford, Monash University, University of Southampton, and Sygnature Discovery. Grey Wolf is headquartered in Oxford, England, UK.
For a complete picture of GRWD-5769’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
